Last reviewed · How we verify
KP-100IT
KP-100IT is a small molecule that targets the S1P1 receptor.
KP-100IT is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | KP-100IT |
|---|---|
| Also known as | Hepatocyte Growth Factor, HGF |
| Sponsor | Kringle Pharma, Inc. |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
KP-100IT works by selectively modulating the sphingosine-1-phosphate 1 (S1P1) receptor, which plays a crucial role in the regulation of immune cell trafficking and function. This mechanism of action has been shown to have therapeutic potential in various inflammatory and autoimmune diseases.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury (PHASE3)
- Phase I/II Study of KP-100IT in Acute Spinal Cord Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KP-100IT CI brief — competitive landscape report
- KP-100IT updates RSS · CI watch RSS
- Kringle Pharma, Inc. portfolio CI